This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (236) Neurology and Neurosciences (117) Safety and Error Prevention in Health (160) Wearable Devices and Sensors (678)

Published on in Vol 10 , No 10 (2021) :October

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/29695, first published .
A New Tool for Safety Evaluation and a Combination of Measures for Efficacy Assessment of Cotransplanting Human Allogenic Neuronal Stem Cells and Mesenchymal Stem Cells for the Treatment of Parkinson Disease: Protocol for an Interventional Study

A New Tool for Safety Evaluation and a Combination of Measures for Efficacy Assessment of Cotransplanting Human Allogenic Neuronal Stem Cells and Mesenchymal Stem Cells for the Treatment of Parkinson Disease: Protocol for an Interventional Study

A New Tool for Safety Evaluation and a Combination of Measures for Efficacy Assessment of Cotransplanting Human Allogenic Neuronal Stem Cells and Mesenchymal Stem Cells for the Treatment of Parkinson Disease: Protocol for an Interventional Study

Authors of this article:

Fatima Jamali 1 Author Orcid Image ;   Mayis Aldughmi 2 Author Orcid Image ;   Mohammad W Khasawneh 1 Author Orcid Image ;   Said Dahbour 3, 4 Author Orcid Image ;   Alaa A Salameh 1 Author Orcid Image ;   Abdalla Awidi 1, 5 Author Orcid Image
Article Authors Cited by (1) Tweetations Metrics

Journals

  1. Soares M, Gonçalves R, Vasques J, da Silva-Junior A, Gubert F, Santos G, de Santana T, Almeida Sampaio G, Silva D, Dominici M, Mendez-Otero R. Current Status of Mesenchymal Stem/Stromal Cells for Treatment of Neurological Diseases. Frontiers in Molecular Neuroscience 2022;15 View